{
    "nct_id": "NCT03961204",
    "official_title": "Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS)",
    "inclusion_criteria": "* Participants with relapsing remitting multiple sclerosis (RRMS) randomised in CLARITY/CLARITY-EXT clinical trial(s) who have received greater than or equal to (>=) 1 course of in investigational medicinal product (IMP) Cladribine Tablets or placebo\n* Participants with their first clinical demyelinating event randomised in ORACLE MS clinical trial who have received >= 1 course of IMP Cladribine Tablets or placebo\n* Participants who has sign informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and this protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Participants who has any uncontrolled disease state other than MS, that in the Investigator's opinion, constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation\n* For study participants at selected sites where MRI assessment will be conducted following exclusion criteria will apply to MRI assessments only:\n* Female study participants who are pregnant\n* Participants who are taking Cladribine Tablets as part of another study at the time of the start of this study",
    "miscellaneous_criteria": ""
}